<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01211639</url>
  </required_header>
  <id_info>
    <org_study_id>101JC403</org_study_id>
    <nct_id>NCT01211639</nct_id>
  </id_info>
  <brief_title>Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy</brief_title>
  <official_title>Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore host genetic mutations which may render individual
      subjects more susceptible (or resistant) to developing Progressive Multifocal
      Leukoencephalopathy (PML). Samples will also be collected to determine Deoxyribonucleic Acid
      (DNA) sequence of JC Virus (JCV). Analysis of the JC Virus (JCV) genome may provide
      information about viral genotypes that may be associated with higher pathogenicity, and help
      to identify individuals who may be at higher risk of developing Progressive Multifocal
      Leukoencephalopathy (PML) due to chronic infection with a more pathogenic variant of JC Virus
      (JCV).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Deoxyribonucleic acid (DNA) will be analyzed from natalizumab-treated subjects who develop
      Progressive Multifocal Leukoencephalopathy (PML). The genetic analysis of the subjects will
      directly seek mutations that could identify subjects at risk.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to lack of enrollment.
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>to examine host genetic variation and possible genetic susceptibility to PML</measure>
    <time_frame>Up to 3 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To explore predisposing factors of the innate and adaptive immune system</measure>
    <time_frame>Up to 3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To analyze DNA sequences of JCV</measure>
    <time_frame>Up to 3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>optional substudy: to test alterations in DNA repair pathways</measure>
    <time_frame>Up to 3 Months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">24</enrollment>
  <condition>Progressive Multifocal Leukoencephalopathy</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood collection for genetic analysis Urine collection for archiving and future
      research use Plasma, Serum, and Peripheral Blood Mononuclear Cells (PBMC) collection for
      archiving and future research use
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study will be conducted in subjects who have confirmed Progressive Multifocal
        Leukoencephalopathy (PML) while being treated with natalizumab.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Subjects who have confirmed PML while on treatment with Natalizumab

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Central Neurology Associates</name>
      <address>
        <city>Cullman</city>
        <state>Alabama</state>
        <zip>35058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain MS Center at Anschutz Medical Campus University Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Medical Center - Rush Multiple Sclerosis Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital, St. Vincent Neuroscience Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Neurology</name>
      <address>
        <city>Hastings</city>
        <state>Nebraska</state>
        <zip>68901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center UH, The Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Hospital for Joint Disease, MS Care Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology of Bend, LLC</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <zip>97701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuerzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2010</study_first_submitted>
  <study_first_submitted_qc>September 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2010</study_first_posted>
  <last_update_submitted>January 15, 2015</last_update_submitted>
  <last_update_submitted_qc>January 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukoencephalopathies</mesh_term>
    <mesh_term>Leukoencephalopathy, Progressive Multifocal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natalizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

